DARPP-32 mediates the actions of multiple drugs of abuse

Apply

DARPP-32 mediates the actions of multiple drugs of abuse

Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 2

Abstract

Drugs of abuse share the ability to enhance dopaminergic neurotransmission in the dorsal and ventral striatum. The action of dopamine is modulated by additional neurotransmitters, including glutamate, serotonin and adenosine. All these neurotransmitters regulate the phosphorylation state of Dopaminal serine/threonine protein phosphatase, PP-1. Phosphorylatine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32). Phosphorylation at Thr34 by protein kinase A converts DARPP-32 into a potent inhibitor of the multifunctioon at Thr75 by Cdk5 converts DARPP-32 into an inhibitor of protein kinase A. The state of phosphorylation of DARPP-32 at Thr34 also depends on the phosphorylation state of Ser97 and Ser130, which are phosphorylated by CK2 and CK1, respectively. By virtue of regulation of these 4 phosphorylation sites, and through its ability to modulate the activity of PP-1 and protein kinase A, DARPP-32 plays a key role in integrating a variety of biochemical, electrophysiological, and behavioral responses controlled by dopamine and other neurotransmitters. Importantly, there is now alarge body of evidence that supports a key role for DARPP-32-dependent signaling in mediating the actions of multiple drugs of abuse including cocaine, amphetamine, nicotine, caffeine, LSD, PCP, ethanol and morphine.

Authors and Affiliations

Per Svenningsson, Angus C. Nairn, Paul Greengard

Keywords

Preparation and characterization of gelatin surface modified PLGA microspheres

This study optimized conditions for preparing and characterizing gelatin surface modified poly (lactic-co-glycolic acid) (PLGA) copolymer microspheres and determined this systems interaction with fibronectin. Some gelati...

A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics

A mathematical pharmacokinetic/anti-drug-antibody (PK/ADA) model was constructed for quantitatively assessing immunogenicity for therapeutic proteins. The model is inspired by traditional pharmacokinetic/pharmacodynamic...

Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products: Workshop Summary Report

Modified release products are complex dosage forms designed to release drug in a controlled manner to achieve desired efficacy and safety. Inappropriate control of drug release from such products may result in reduced ef...

Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume

The online version of this article (doi:10.1208/s12248-016-9885-2) contains supplementary material, which is available to authorized users.

EP ID EP681858
DOI 10.1208/aapsj070235
Views 95
Downloads 0